Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiTAN-1: GEN-011 in advanced solid tumors
NCT04596033Phase 1Terminated
- Sponsor
- Genocea Biosciences
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEN-011 in melanoma, non-small cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 6 more (2 arms), sponsored by Genocea Biosciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 years. Started Nov 2020; status: terminated.
02
Drugs
GEN-011
03
Conditions
melanomanon-small cell lung carcinoma (NSCLC)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04596033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596033.